Selvita will present at BIO-Europe Spring 2017

Kraków, Poland – 15 March 2017 – Selvita will participate and present at the upcoming BIO-Europe Spring 2017 conference, which is to take place on March 20-22, 2017, in Barcelona, Spain. Selvita will be presenting in the Oncology category. The presentation will be held by Mr. Pawel Przewiezlikowski, Chief Executive…

More

Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry

Kraków, Poland – 13 February 2017 – MNK1 and MNK2 are MAP kinase-interacting serine/threonine kinases, which are activated by RAS and MAPK signaling pathways and are involved in regulation of protein translation. A growing number of reports on developments of novel, selective inhibitors of MNK1/2 kinases, has prompted a group…

More

Selvita announces a ten-year laboratory infrastructure development plan

Krakow, Poland – 22 September 2016 – Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, has signed a preliminary agreement to purchase a land property in Krakow, Poland, where it plans to build its future drug discovery laboratories. The land property size is 1.4 hectares and…

More

Selvita to present at Biotech Showcase 2017 in San Francisco

Krakow, Poland – 16 December 2016 – Selvita (WSE:SLV), a drug discovery company, announced today that its Chief Scientific Officer, Krzysztof Brzozka, will present at the upcoming Biotech Showcase Annual Conference, to be held in San Francisco on January 9 – 11, 2017. The Biotech Showcase conference is one of…

More

Selvita will be exhibiting at the 5th MassBio CRO/CMO Symposium

Krakow, Poland – December 1, 2016 – Selvita will be exhibiting at the 5th Annual  MassBio CRO/CMO Symposium at the Boston Marriott Cambridge, on Thursday, December 8, 2016. This symposium brings together participants from the Boston life sciences cluster to discuss the best practices required to reduce time to market….

More

...34567...10...